PolyProx Therapeutics is a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer.
PolyProx is developing a new class of drugs, PolyproxinTM molecules, that selectively target tumour cells and trigger the natural degradation machinery contained with the cell to arrest tumour growth.
PolyProx’s approach has the potential to address cancer targets that have proven untreatable using current technologies, important in major diseases such as lung, colorectal and pancreatic cancers.
PolyProx was launched in April 2019 and is a spin out from the Department of Pharmacology at the University of Cambridge based on the over a decade of research and intellectual property creation from founder Professor Laura Itzhaki’s laboratory.
CIC point of contact: Michael Anstey